Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYVBF6)

Drug Name

Edasalonexent Drug Info

Synonyms

UNII-AF3Z6434KS; AF3Z6434KS; 1204317-86-1; Edasalonexent [INN]; SCHEMBL1823117; CHEMBL3786673; JQLBBYLGWHUHRW-KUBAVDMBSA-N; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide; Benzamide, 2-hydroxy-N-(2-(((4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl)amino)ethyl)-; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16, 19-hexaenamidoethyl)-2-hydroxybenzamide

Indication

Disease Entry	ICD 11	Status	REF
Duchenne dystrophy	8C70	Phase 3	[1]

Cross-matching ID

PubChem CID: 44626120
CAS Number: CAS 1204317-86-1
TTD Drug ID: DMYVBF6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nuclear factor NF-kappa-B (NFKB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[3]
Triptolide	DMCMDVR	Autoimmune diabetes	5A10	Phase 3	[4]
Laquinimod	DM3IWS8	Lupus	4A40	Phase 3	[5]
MD1003	DMVZ57G	Multiple sclerosis	8A40	Phase 3	[2]
Vadimezan	DMK7CYX	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
CAT 1004	DMQBP7R	Duchenne dystrophy	8C70	Phase 2	[7]
Parthenolide	DMCQBFT	N. A.	N. A.	Phase 2	[8]
Recoflavone	DMCSR8I	Inflammatory bowel disease	DD72	Phase 2	[9]
CZEN-002	DMUDMHA	Fungal infection	1F29-1F2F	Phase 2	[10]
XP-23829	DMELUYN	Multiple sclerosis	8A40	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear factor NF-kappa-B (NFKB)	TTSXVID	NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03917719) An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (GalaxyDMD). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
4	Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
5	Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
6	Auckland Cancer Society Research Centre report
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
9	DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
10	US patent application no. US20100278784 A1.
11	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036491)